70 million + expiring doses of H1N1 Vaccine that went unused...

[www.foxnews.com]

I heard this on the radio this morning and just thought, "Not this again . . . "

I guess someone needs to recoup their market share. [sigh]

This time it looks like they might need a real virus in order to sell a trial vaccine, sorry Donald better scare next time.

At least he was ethical and didn't release something really scary, like smallpox. Also, do you think they might credit the vaccination campaign with the non-epidemic? About half the people I know got vaccinated.

tropical Wrote:
-------------------------------------------------------
> At least he was ethical and didn't release
> something really scary, like smallpox. Also, do
> you think they might credit the vaccination
> campaign with the non-epidemic? About half the
> people I know got vaccinated.


They can spin it anyway they need to...

Low vax demand could threaten H1N1 profits


Related Stories
Sanofi recalls pediatric H1N1 shots
Flu-remedy news spreads along with virus
Israel wants flu vax made at home
Swine flu could be FluMist's moment
GSK allows Brits to cut H1N1 vax order by one-third

Some European customers are negotiating to return millions of unused doses of H1N1 vaccine to four suppliers, threatening the companies' huge revenue boost from the global pandemic. Apparently, governments had expected people to turn out in big numbers for the shot, but that isn't happening--and so the buyers want their money back.

Analysts estimate that sales of flu shots from GlaxoSmithKline, Sanofi-Aventis, Novartis and AstraZeneca could be 15 percent lower than initially thought. In GlaxoSmithKline's case, that would amount to a £330 million ($534 million) reduction. The company had collected enough vaccine orders to boost its 2009 revenues up by £1 billion ($1.6 billion), and that total was expected to grow to £2.2 billion ($3.5 billion) over the course of the pandemic. Sales boosts for the other companies had been expected to be smaller, with Sanofi predicted to gain €750 million ($1.07 billion) and Novartis €600 million ($860 million), so at a 15 percent reduction, they'd lose commensurately less.

Only 20 percent of the high-risk groups in Spain showed up for the vaccine; that country had ordered 14.7 million doses. Meanwhile, in Germany, which ordered 50 million doses, officials believe people will need only one dose apiece rather than two, so they're looking to cut back on that order.

Spanish officials say they've made headway in getting the companies to take back the unneeded shots: "The contracts ... included clauses which allow the return of unused vaccines so they can be distributed to other countries," Health Minister Trinidad Jiminez told reporters. And a Glaxo spokesman told the Mail that the company "continue to support governments in managing the H1N1 influenza pandemic. This includes ongoing discussions for existing and new orders for our pandemic vaccines." We'll have to wait and see how those discussions pan out.



Read more: [www.fiercepharma.com]

hehe the pandemic that never was

...Jodi, the banana eating buddhist

Jgunn Wrote:
-------------------------------------------------------
> hehe the pandemic that never was

Again.